Haleos Labs Limited (BOM:540679)

Market Cap	3.47B
Revenue (ttm)	3.35B
Net Income (ttm)	173.16M
Shares Out	n/a
EPS (ttm)	57.27
PE Ratio	20.06
Forward PE	n/a
Dividend	1.50 (0.13%)
Ex-Dividend Date	Sep 24, 2025

Volume	163
Average Volume	379
Open	1,091.50
Previous Close	1,091.50
Day's Range	1,085.70 - 1,178.35
52-Week Range	956.05 - 1,747.85
Beta	n/a
RSI	49.26
Earnings Date	Aug 12, 2025

About Haleos Labs

Haleos Labs Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant. In addition, the company offers intermediates in the anti ulcer, anti m...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 574
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 540679

Financial Performance

In 2024, Haleos Labs's revenue was 3.45 billion, an increase of 12.67% compared to the previous year's 3.06 billion. Earnings were 201.09 million, an increase of 121.15%.